This pilot phase I trial studies the side effects and how well MUC1 peptide-Poly-ICLC vaccine
works in preventing lung cancer in current and former smokers at high risk for lung cancer.
Vaccines made from peptides may help the body build an effective immune response to kill
cells. MUC1 peptide-Poly-ICLC vaccine may stimulate the body's immune system and slow or stop
the changes from normal to pre-cancer to cancer.